360° SearchNetwork Hot Spots Trends Time Series

Alimta

Type: Product

Name: Alimta

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Another setback for Lilly as lymphoma drug fails

Late-stage candidate enzastaurin shows disappointing phase III resultsEli Lilly has racked up another late-stage pipeline disappointment, dropping lymphoma drug candidate enzastaurin from development after it failed a phase III trial.The results of the ... [Published PMLive - May 13 2013]

Entities: Eli Lilly & Company, lymphoma, Phase III, non-small cell lung cancer, Drugs

First reported May 10 2013 - Updated May 11 2013 - 2 reports

Eli Lilly lymphoma drug fails in late-stage trial

( ) - Eli Lilly The drug, enzastaurin, was being tested in lymphoma patients The decision to stop the drug's development will result in a second-quarter charge of about $30 million, but the company's 2013 forecast remained unchanged, Lilly said in a statement ... [Published Yahoo! - May 10 2013]

Entities: Eli Lilly & Company, lymphoma, Drugs, Lung Cancer, Alimta

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Medicare cuts pit patients needing chemo against cancer and Congress

FORT WORTH At The Center for Cancer and Blood Disorders, patients get treatment in a personal setting. They're in the fight of their lives, battling cancer... and now Congress. "Your main concern is dealing with the disease," said five-year cancer survivor ... [Published WFAA.com - Apr 23 2013]

Entities: Patient, Cancer, Medicare

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Eli Lilly Earnings Preview: EPS, Sales Growth Expected

Eli Lilly (NYSE: LLY), which last week announced a deal to buy two imaging agents from Siemens (NYSE: SI) that could help aid the fight against Alzheimer's, is scheduled to report its first-quarter 2013 results Wednesday, April 24, before the markets ... [Published Benzinga.com - Apr 23 2013]

Entities: Eli Lilly & Company, Zyprexa, Cymbalta

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Clinical Trials Helped One Woman's Fight Against Cancer

Font SizeAAAClinical Trials Helped 1 Woman's Cancer BattleAnd new tool for finding the right match may help others get novel treatmentsWebMD News from HealthDayBy Barbara Bronson GrayHealthDay ReporterTHURSDAY, April 18 (HealthDay News) -- Monica Barlow, ... [Published WebMD - Apr 18 2013]

Entities: Clinical trials, Tumor, Cancer

First reported Feb 25 2013 - Updated Feb 25 2013 - 1 reports

Eli Lilly & Company

EndOfLifeConsiderations Fail To Save Lillys Alimta For NSCLC At NICE

Home » Blogs » End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICERelated Biotechnology, Pharmaceutical and Healthcare NewsBritain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. ... [Published BioPortfolio - Feb 25 2013]

Entities: Alimta, non-small cell lung cancer, Eli Lilly & Company

First reported Feb 22 2013 - Updated Feb 22 2013 - 1 reports

NICE consults on pemetrexed for the maintenance treatment of non-small-cell lung cancer

NICE, the healthcare guidance body, has issued new draft guidance not recommending pemetrexed (Alimta, Eli Lilly) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin. ... [Published NICE | National Institute for Health and Clinic ... - Feb 22 2013]

Entities: Pemetrexed, Lung Cancer, induction therapy, Alimta, cisplatin

First reported Feb 22 2013 - Updated Feb 22 2013 - 1 reports

NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance

Home » Syndicated Content » UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft guidance not recommending US pharma major Eli Lilly's Alimta (pemetrexed) for the maintenance treatment of non-small-cell ... [Published BioPortfolio - Feb 22 2013]

Entities: Alimta, National Institute for Health & Clinical Excell..., non-small cell lung cancer, Eli Lilly & Company

First reported Feb 06 2013 - Updated Feb 06 2013 - 1 reports

ALIMTA (Pemetrexed Disodium) Injection, Powder, Lyophilized, For Solution [Eli Lilly And Company]

Updated Date: Feb 5, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 06 2013]

Entities: pemetrexed disodium, Alimta, Eli Lilly & Company

First reported Jan 31 2013 - Updated Jan 31 2013 - 1 reports

Eli Lilly's net slips by 3.6% to $827 mn in Q4

Eli Lilly and Company has suffered a setback during the fourth quarter ended December 2012 and its net profit declined by 3.6 per cent to $827 million from $858 million in the corresponding period of last year mainly due expiration of patient for Zyprexa. ... [Published PharmaBiz - Jan 31 2013]

Entities: Eli Lilly & Company, Zyprexa, Cymbalta, Declination

First reported Jan 29 2013 - Updated Jan 30 2013 - 2 reports

Lilly hit by Zyprexa losses | Pharmafile

Published on 30/01/13 at 11:33am The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall revenue falling 7% worldwide. The drug itself, licensed to treat schizophrenia and ... [Published PharmaGossip - Jan 30 2013]

Entities: Eli Lilly & Company, Zyprexa, John Lechleiter, Cymbalta

First reported Jan 04 2013 - Updated Jan 04 2013 - 2 reports

Tranzyme Partners with Bristol-Myers, Lilly Fights Patent Cliff: Healthcare Business Recap

Tranzyme Pharma ( NASDAQ:TZYM ) Closing price $0.52 On Friday, Tranzyme reported the successful finalization of its chemistry-based drug discovery partnership with Bristol-Myers Squibb Company ( NYSE:BMY ). Resulting from their research efforts, ... [Published Wall St. Cheat Sheet - Jan 04 2013]

Entities: Tranzyme Inc, Eli Lilly & Company, Johnson & Johnson, Patent, Bristol-Myers Squibb Company

Quotes

"However, our oncology pipeline is still one of the most robust across the industry containing more than 20 molecules, including two phase III molecules in five different tumour types" he added

Another setback for Lilly as lymphoma drug fails [Published PMLive - May 13 2013]

..." Mr. Ehrlich continued, "Signing a CDA does not mean a licensing deal or other transaction is imminent and makes no assumptions that it ever will. But, conversely, a deal won't ever happen without first signing a CDA. At Cellceutix, we are focused on moving our compounds toward clinical trials and maximizing shareholders' value. This agreement is one more step in that process."

Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [Published Seeking Alpha - May 10 2013]

...information contained in our Annual Report on Form 10-K for the year ended July 31, 2012 and presume readers have access to, and will have read, the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other information contained in such Form 10-K...

TAMIR BIOTECHNOLOGY, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN ... [Published Pharmacy Choice - May 04 2013]

"Safety will be scrutinized because it will be compared with BMS' (Bristol-Myers Squibb) dapagliflozin, which got a CRL (complete response letter) owing to safety concerns (liver tox., question about use in renally impaired patients)" BMO Capital Markets analyst Alex Arfaei said in a client note

Eli Lilly And Company: Focus On Pipeline Intensifies As Franchises Weakening [Published I Stock Analyst - Apr 29 2013]

More Content

sort by: Date \| Relevance
Another setback for Lilly as lymphoma drug fails [Published PMLive - May 13 2013]
Eli Lilly lymphoma drug fails in late-stage trial [Published Yahoo! - May 10 2013]
UPDATE 1-Eli Lilly lymphoma drug fails in late-... [Published CNBC - May 10 2013]
Cellceutix Corporation: The Next Generation Of ... [Published Seeking Alpha - May 10 2013]
Discovery Chicago Hires Two Senior Vice Preside... [Published PRWeb - May 07 2013]
TAMIR BIOTECHNOLOGY, INC. - 10-Q - MANAGEMENT'S... [Published Pharmacy Choice - May 04 2013]
Eli Lilly And Company: Focus On Pipeline Intens... [Published I Stock Analyst - Apr 29 2013]
Eli Lilly Earnings Preview: EPS, Sales Growth E... [Published Benzinga.com - Apr 23 2013]
Medicare cuts pit patients needing chemo agains... [Published WFAA.com - Apr 23 2013]
Clinical Trials Helped One Woman's Fight Agains... [Published WebMD - Apr 18 2013]
Clinical Trials Helped One Woman's Fight Agains... [Published Health Finder - Apr 18 2013]
A Look at LLY's Early Stage Oncology Pipeline Z... [Published Yahoo! Finance - Apr 12 2013]
EndOfLifeConsiderations Fail To Save Lillys Ali... [Published BioPortfolio - Feb 25 2013]
NICE draft guidance rejects Eli Lilly's Alimta ... [Published BioPortfolio - Feb 22 2013]
NICE consults on pemetrexed for the maintenance... [Published NICE \| National Institute for Health and Clinic ... - Feb 22 2013]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING:RBS... [Published Proactiveinvestors United Kingdom RSS feed - Feb 22 2013]
ALIMTA (Pemetrexed Disodium) Injection, Powder,... [Published DailyMed Drug Label Updates for the last seven ... - Feb 06 2013]
Deals Of The Weeks Wonders If A Biopharma Super... [Published The IN VIVO Blog - Feb 01 2013]
Eli Lilly's net slips by 3.6% to $827 mn in Q4 [Published PharmaBiz - Jan 31 2013]
Lilly hit by Zyprexa losses \| Pharmafile [Published PharmaGossip - Jan 30 2013]
Eli Lilly Earnings: Exceeds Estimates [Published Wall St. Cheat Sheet - Jan 29 2013]
Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013]
Eli Lilly: Buy, Sell Or Hold [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 09 2013]
Tranzyme Partners with Bristol-Myers, Lilly Fig... [Published Wall St. Cheat Sheet - Jan 04 2013]
Analysis: Alimta patent seen as Lilly's "wild c... [Published Reuters: Business News - Jan 04 2013]
FDA clears new use for Eli Lilly's Alimta [Published BioPortfolio - Oct 19 2012]
FDA approves Eli Lilly Alimta as continuation m... [Published BioPortfolio - Oct 18 2012]
ALIMTA&174; Extends Survival in Continuation… [Published BioPortfolio - Oct 18 2012]
Alimta Lung Cancer Label Expanded To Include Lo... [Published BioPortfolio - Oct 17 2012]
A Skeptical Take On Eli Lilly [Published BioPortfolio - Oct 13 2012]

Blogs

sort by: Date \| Relevance
NICE consults on pemetrexed for the maintenance... [Published NICE \| National Institute for Health and Clinic ... - Feb 22 2013] NICE, the healthcare guidance body, has issued new draft guidance not recommending pemetrexed (Alimta, Eli Lilly) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin. ...
ALIMTA (Pemetrexed Disodium) Injection, Powder,... [Published DailyMed Drug Label Updates for the last seven ... - Feb 06 2013] Updated Date: Feb 5, 2013 EST ...
Deals Of The Weeks Wonders If A Biopharma Super... [Published The IN VIVO Blog - Feb 01 2013] Deals of the Week is torn as the Super Bowl approaches – you see, most of this feature’s contributors live either in 49ers country near San Francisco or in the case of this author, a short drive from the home field of the Baltimore Ravens. With our ...
Lilly hit by Zyprexa losses \| Pharmafile [Published PharmaGossip - Jan 30 2013] Published on 30/01/13 at 11:33am The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall revenue falling 7% worldwide. The drug itself, licensed to treat schizophrenia and ...
Eli Lilly Earnings: Exceeds Estimates [Published Wall St. Cheat Sheet - Jan 29 2013] Eli Lilly & Co. ( NYSE:LLY ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.25%. Markets are at 5-year ...